SEC Form 4 · accession 0001437749-15-016752
Impax Laboratories, LLC · IPXL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Markbreiter
Director
Period of report
Aug 28, 2015
Accepted (ET)
Sep 1, 2015 · 6:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001003642
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 28, 2015 | M | 8,000 | $17.99 | A | 16,200 | D | |
| Common StockF1 | Aug 28, 2015 | S | 8,000 | $42.48 | D | 8,200 | D | |
| Common Stock | Aug 31, 2015 | M | 10,000 | $20.90 | A | 18,200 | D | |
| Common StockF2 | Aug 31, 2015 | S | 10,000 | $41.39 | D | 8,200 | D | |
| Common Stock | Aug 31, 2015 | M | 10,000 | $20.30 | A | 18,200 | D | |
| Common StockF3 | Aug 31, 2015 | S | 10,000 | $41.39 | D | 8,200 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $17.99 | Aug 28, 2015 | M | 8,000 | D | — | May 15, 2023 | Common Stock | 8,000 | 4,000 | D |
| Stock Option (Right to Buy)F5 | $20.90 | Aug 31, 2015 | M | 10,000 | D | — | May 23, 2022 | Common Stock | 10,000 | 0 | D |
| Stock Option (Right to Buy)F5 | $20.30 | Aug 31, 2015 | M | 10,000 | D | — | May 26, 2020 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $42.29 to $42.71 in multiple transactions. The reporting person undertakes to provide to Impax Laboratories, Inc., any security holder of Impax Laboratories, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $40.39 to $42.75 in multiple transactions. The reporting person undertakes to provide to Impax Laboratories, Inc., any security holder of Impax Laboratories, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $40.39 to $42.75 in multiple transactions. The reporting person undertakes to provide to Impax Laboratories, Inc., any security holder of Impax Laboratories, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- F4Of the 12,000 shares underlying the options, 8,000 of the shares subject to the option are fully vested and exercisable.
- F5100% of the shares subject to the option are fully vested and exercisable.
Remarks
The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.